Skip to content
Taxonomy
TAKE ACTION! Sign the Petition to Accelerate CMT-SORD
What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding, Read More
CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA Alliance Partner, NMD Pharma, Announces Encouraging Data with Implications for CMT
Charcot-Marie-Tooth Association (CMTA) Alliance Partner, NMD Pharma, announced the publication Read More
Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research
The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing Read More
The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
It is with the heaviest of hearts that the Charcot-Marie-Tooth Read More
CMT2S Breakthrough
In a recent announcement, Vanda Pharmaceuticals Inc. shared that the Read More
CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for CMT-SORD
In a statement released on February 15, 2024, by Charcot-Marie-Tooth Read More
The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT
Multisite and multiyear collaborative project led by a team of Read More
ToolGen CMT1A Treatment Receives Orphan Drug Designation
CMTA Alliance Partner ToolGen announced December 18, 2023 that it Read More
